June 28th 2021

Editor-in-Chief
World Journal of Clinical Oncology

Dear Editor,

Thank you for the letter of June 17th, 2021, suggesting major revisions (Manuscript NO: 67141, Title: 'Increased level of TNS4 expression is related to the histological type of gastric cancer', for publication in the World Journal of Clinical Oncology.

We found the comments and suggestions of the Editor and Reviewer helpful, and have made revisions accordingly.

We hope that the revised manuscript has satisfied the Editor and Reviewer. We thank you for your consideration and await your decision.

Yours Sincerely,

Anna Pryczynicz, Ph.D.
Department of General Pathomorphology
Medical University of Bialystok
Kilinskiego 1
15-089 Bialystok, Poland
Telephone: (48) (85) 748 5991
E-mail: anna.pryczynicz@umb.edu.pl

Response to Editor

We would like to thank the Editor for comments.

All required certificates/forms were signed by all of the authors. Additionally, the authors provided a signed conflict of interest disclosure form, copyright license agreement, and written informed consent. The authors submitted the approved grant application form, however, in polish. Original pictures were provided as PowerPoint presentation. The reference list was supplemented with PMID and DOI numbers and the “Article Highlights” section was added.

Response to Reviewer

We would like to thank the Reviewer for constructive comments.

Reviewer #1

This work is aim to investigate TNS4 protein expression in GC tissues and analysis with clinical and histopathological parameters. However, the TNS4 expression in GC patients has been reported, so, the novelty of this topic is lacking.

We agree with the Reviewer's opinion that there are several investigations concerning the analysis of the expression of TNS4 in gastric cancer, however, in our study, we applied many more GC clinicopathological parameters than other authors. We also observed additional associations between TNS4 protein expression and the selected clinical features which allow us to expand the knowledge about the significance of this protein in GC development.

Moreover, there are major weaknesses need to be improved:

1. Though TNS4 expression was investigated in GC patients, just 89 GC patients used in this study are far from sufficient to verify clinical significance. We strongly suggested that a larger GC cohort should be used for further verification.

Thank you for this comment and we strongly agree with your opinion. Collecting samples and preparing a base containing clinical data is time-consuming and we are not able to perform a study on a larger cohort in such a short time. However, in our future study, we will implement a larger patient group.

2. Loss of function strategy should be used to investigate the potential role of TNS4 in cell proliferation using GC cell lines in vitro and in vivo.

We completely agree with your opinion that in vitro study of the potential role of TNS4 protein in GC development would reflect its involvement in the aforementioned process. Performing this type of investigation needs resources and equipment we do not have at our lab. However, in our future study, we would like to cooperate with the cell culture lab to perform more completed studies.